Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting.
Pomella S, Cassandri M, D'Archivio L, Porrazzo A, Cossetti C, Phelps D, Perrone C, Pezzella M, Cardinale A, Wachtel M, Aloisi S, Milewski D, Colletti M, Sreenivas P, Walters ZS, Barillari G, Di Giannatale A, Milano GM, De Stefanis C, Alaggio R, Rodriguez-Rodriguez S, Carlesso N, Vakoc CR, Velardi E, Schafer BW, Guccione E, Gatz SA, Wasti A, Yohe M, Ignatius M, Quintarelli C, Shipley J, Miele L, Khan J, Houghton PJ, Marampon F, Gryder BE, De Angelis B, Locatelli F, Rota R. Pomella S, et al. Among authors: de angelis b. Nat Commun. 2023 Dec 15;14(1):8373. doi: 10.1038/s41467-023-44130-0. Nat Commun. 2023. PMID: 38102140 Free PMC article.
Overcoming Challenges in CAR T-cell Product CGMP Release.
Quintarelli C, Locatelli F, Caruana I, De Angelis B. Quintarelli C, et al. Among authors: de angelis b. Mol Ther. 2016 May;24(5):845-6. doi: 10.1038/mt.2016.72. Mol Ther. 2016. PMID: 27198849 Free PMC article. No abstract available.
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.
Bocca P, Di Carlo E, Caruana I, Emionite L, Cilli M, De Angelis B, Quintarelli C, Pezzolo A, Raffaghello L, Morandi F, Locatelli F, Pistoia V, Prigione I. Bocca P, et al. Among authors: de angelis b. Oncoimmunology. 2017 Oct 4;7(1):e1378843. doi: 10.1080/2162402X.2017.1378843. eCollection 2017. Oncoimmunology. 2017. PMID: 29296542 Free PMC article.
Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.
Orlando D, Miele E, De Angelis B, Guercio M, Boffa I, Sinibaldi M, Po A, Caruana I, Abballe L, Carai A, Caruso S, Camera A, Moseley A, Hagedoorn RS, Heemskerk MHM, Giangaspero F, Mastronuzzi A, Ferretti E, Locatelli F, Quintarelli C. Orlando D, et al. Among authors: de angelis b. Cancer Res. 2018 Jun 15;78(12):3337-3349. doi: 10.1158/0008-5472.CAN-17-3140. Epub 2018 Apr 3. Cancer Res. 2018. PMID: 29615432
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.
Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, Giorda E, Scarsella M, Petrini S, Pagliara D, Locatelli F, De Angelis B, Caruana I. Quintarelli C, et al. Among authors: de angelis b. Oncoimmunology. 2018 Mar 15;7(6):e1433518. doi: 10.1080/2162402X.2018.1433518. eCollection 2018. Oncoimmunology. 2018. PMID: 29872565 Free PMC article.
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA, Cristantielli R, Weber G, Del Bufalo F, Belardinilli T, Arnone CM, Petretto A, Antonucci L, Giorda E, Tumino N, Pitisci A, De Angelis B, Quintarelli C, Locatelli F, Caruana I. Polito VA, et al. Among authors: de angelis b. Front Immunol. 2019 Nov 22;10:2717. doi: 10.3389/fimmu.2019.02717. eCollection 2019. Front Immunol. 2019. PMID: 31824502 Free PMC article.
155 results